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ABSTRACT
32P has been available for the treatment of myeloproliferative neoplasms (MPNs) for over seventy years.  It was first used in 
1938 by John H Lawrence in the treatment of polycythaemia and chronic leukaemias.  With the introduction of agents such as 
hydroxycarbamide, interferon and anagrelide the role of 32P has been diminished.  Today, Polycythaemia Rubra Vera (PRV) and 
Essential Thrombocythaemia (ET) remain the only myeloproliferative conditions in which 32P is indicated.  
Materials and Methods We carried out a retrospective review of all patients who had received 32P in Northern Ireland over a 
24 year period.  The time to successful response, duration of response, and associated complications were reviewed.
Results 32P was successful in inducing remission in 90% of patients. This remission was sustained following one dose without 
the need for further therapy in 37% of cases.  47% required repeated doses.  26% required recommencement of alternative 
therapies.  No cases of thrombosis, myelofibrosis or acute leukaemia were observed. 
Discussion We conclude that 32P is a well-tolerated and efficacious treatment option in the elderly. We discuss our results 
compared with previous work in this area. 32P will continue to be offered to elderly patients in our practice.
Keywords: Polycythemia rubra vera, Essential Thrombocythemia, Radioactive phosphorous 
32P IN THE TREATMENT OF 
MYELOPROLIFERATIVE DISORDERS
32P has been available for the treatment of myeloproliferative 
neoplasms for over seventy years.  It was first used in 
1938 by John H Lawrence to treat polycythaemia and 
chronic leukaemias1,2. Concerns were however raised over 
its leukaemogenic potential.  It has become a therapeutic 
modality of the past for chronic leukaemias and with the 
introduction of other agents such as hydroxycarbamide 
and interferon in polycythaemia and anagrelide in essential 
thrombocythaemia, the role of 32P has been diminished. 
Today, polycythaemia rubra vera (PRV) and essential 
thrombocythaemia (ET) remain the only myeloproliferative 
conditions in which 32P is indicated3,4.  
We carried out a retrospective review of all patients who had 
received 32P in Northern Ireland over a 24-year period.
All patients were under the care of a consultant haematologist. 
They were referred to a clinical oncologist to receive 32P in 
a designated nuclear medicine unit.  All patients received 
185mq of 32P.  
METHODS
 All patients who received 32P were under the care of a clinical 
oncologist.  A database with records of all patients treated 
with 32P since 1988 is kept within the nuclear medicine unit 
of the Northern Ireland Cancer Centre and this was used to 
identify patients.  
Patient characteristics were reviewed including age, diagnosis 
and previous treatments.  
Response was defined as return of blood counts to normal 
(HCT <0.45 platelets <450x109/l). The time to successful 
response was reviewed along with the duration of response. 
Length of follow up was recorded and whether or not 32P was 
required again. Case notes were reviewed for any signs of 
complications from 32P.
RESULTS
A total of nineteen patients were identified as having received 
32P over a 24-year period (1988-2012).  Eight men and eleven 
women were included. Of these 15 subjects suffered from ET 
and 4 from PRV.  
The median age at the first dose of 32P was 80 years with ages 
ranging from 68 to 90 years at first dose. 
All patients had received treatment with hydroxycarbamide 
prior to referral for 32P.  This was generally stopped due to the 
development of leg ulcers or anaemia.  Of the PRV patients 
busulfan had also been used in one patient.  Myelobromol 
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had also been used in one patient and all four had received 
venesection as a means of controlling haematocrit prior to 
referral for 32P.  Of the patients with ET, anagrelide had been 
used in three patients and myelobrommol had also been used 
in three patients.  Two patients, one with ET and one with 
PRV, had both previously been treated with vorinostat within 
a clinical trial.  (Figure 1)
Fig 1. Previous treatments prior to 32P. 
32P was successful in reducing counts to acceptable levels in 
all but 2 patients (89% response rate).
Time to response varied between 3 weeks to 8 weeks with a 
median time to response being five weeks.
Seven patients (37%) required only one dose of 32P to achieve 
a successful response which, to date has been sustained. These 
patients have not required any further treatment. The longest 
duration of response to date in this group is 156 weeks. 
However not all patients had a sustained response. In those 
that went on to relapse, the duration of response varied 
between 4 weeks to 20 weeks with the median response being 
18 weeks. Eight of these patients went on to receive further 
32P. Therefore 32P was given more than once in a total of 9 
patients with 6 receiving it twice, 2 receiving it three times 
and one patient receiving it four times. Five patients (26%) 
required recommencement of alternative therapies.
Length of follow up varied from 7 months to 24 years, with 
a median follow up of 21 months. 
None of the patients in this review who received 32P 
experienced any adverse haematological effects, in particular 
there were no cases of myelofibrosis, thrombosis or 
progression to leukaemia. One patient was later diagnosed 
with renal cell carcinoma. No other carcinomas were 
diagnosed post treatment.
DISCUSSION
Myeloproliferative neoplasms (MPN) are a heterogeneous 
group of disorders characterized by cellular proliferation of 
one or more haematologic cell lines in the peripheral blood5. 
They were first recognised by William Dameshek in 1951 
and include polycythaemia rubra vera (PRV) and essential 
thrombocythaemia (ET)5.
32P offers an alternative treatment option. It was first used in 
1938 by John H Lawrence for the treatment of polycythaemia 
and chronic leukaemias1. It is a pure beta emitter with a half-
life of 14.3days and is administered as an injection2.  It was 
initially recognised through preliminary work in mice that a 
large proportion of the injected dose became rapidly localised 
within the bone marrow and a few days later in bone with 
smaller quantities seen in the liver, spleen and lymph nodes6. 
It acts by incorporation of the 32P orthophosphate into the 
nuclei of rapidly proliferating and protein synthesising cells. It 
is also taken up by the hydroxyapatite moiety of bone crystals 
in cortical bone. Radiation protection for staff from a pure 
beta emitter is straightforward.
PRV is the most extensively studied of the MPNs treated with 
32P2. Following Lawrence’s work in 1939, the most effective 
treatment of PRV included phlebotomies combined with 32P5. 
Concern was however raised in 1948 that patients treated with 
32P may develop acute leukemia2.
The Polycythaemia Vera Study Group (PVSG) was 
organized in 1967 to establish effective diagnostic criteria 
for polycythaemia rubra vera, to study the natural history 
of the disease and to define the optimal treatment7.  Its first 
study compared 32P, chlorambucil and phlebotomy in 431 
patients in a randomised trial2,5,7.  It was found that patients 
treated with chlorambucil carried an excessive risk of acute 
leukaemia, and therefore this arm was discontinued.  Patients 
treated with phlebotomy alone showed a higher incidence of 
thrombosis in the first 3 years of treatment5. After 3 to 5 years 
of study, a considerable number of patients treated with 32P 
or chlorambucil developed acute leukaemia, lymphoma and 
carcinomas of the gastrointestinal tract and skin, compared 
with those treated with phlebotomy alone5. Therefore, patients 
treated with phlebotomy alone had a better overall median 
survival of 13.9 years than patients treated with chlorambucil 
(8.9 years) or 32P (11.8 years)5,7.
However, rates of acute leukaemia of up to 14% in PRV 
patients have been reported, which may imply that acute 
leukaemia is the natural progression for some patients with 
PRV3.  The incidence in randomised trials after 32P alone is 
2.5% to 15%3.
The effectiveness of 32P was also demonstrated by Balan et 
al who examined its use in 259 patients with PRV and ET 
over a 15 year period8.  They found normalisation of counts 
in 50% patients after a single administration and in 73% 
after two treatments.  With regards to complications; 5.5% 
developed myelofibrosis, 7.6% developed leukaemia, while 
other cancers were found in 9% of cases8.  
Randi et al also looked specifically at haematological 
complications post 32P therapy9. Their review included 230 
patients with MPNs.  None of the patients with ET developed 
haematological complications.  Of the PRV patients, 17% 
developed complications.   Sixty percent of these were 
classified as minor complications such as transient anaemia 
or thrombocytopenia.  Only 7% had major complications with 
acute leukaemia developing in 5%. 
The use of 32P alone or in combination with hydroxycarbamide 
has also been examined.  Najean et al randomised 461 
patients over the age of 65 to receive hydroxycarbamide or 
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no hydroxycarbamide after their first 32P induced remission10. 
It was found that hydroxycarbamide significantly prolonged 
the duration of 32P induced remission and reduced the 
annual mean dose received by a third. The rate of vascular 
complications was not decreased however. While the 
leukaemia risk was significantly increased, a significant 
excess of other carcinomas was also observed.
More recently Bjorkholm et al used data from population 
based registries in Sweden to conduct a large study 
examining to what extent cytoreductive therapies contribute 
to leukaemic and myelodysplastic transformation in patients 
with MPN11. While the focus of the study was on the effects 
of hydroxycarbamide, 32P was also reviewed.  The risk of 
AML/MDS transformation was strongly associated with 
high exposure of 32P and alkylating agents. This equated to 
cumulative doses of 1,000MBq.  Lower exposure to 32P and 
alkylating agents was not associated with a significantly 
increased transformation risk. More importantly, 25% of 
patients with transformation to AML/MDS were never 
exposed to 32P, hydroxycarbamide or alkylating agents. 
Furthermore, only 32% of patients with transformed disease 
were exposed to cumulative doses of 32P and/or alkylating 
agents. The authors concluded that the risk of transformation 
to leukaemia or myelodysplasia is mainly associated with 
the disease itself, with exposure to cytoreductive agents of 
less importance. This study however may indicate a need 
for a threshold exposure to 32P given the increased risk of 
transformation at higher doses.
Due to its increased risk of leukaemic transformation, the 
British Committee for Standards in Haematology advise that 
32P use should be limited to the elderly3,4.  
Our review has shown that 32P was able to induce remission 
in 90% of cases, whilst 37% of cases required only one 
dose to provide a sustained remission to date. While some 
cases required repeated doses of 32P, only 26% required to 
return to alternative treatments. No adverse haematological 
complications have been observed to date. Our review is 
limited by the small number of cases, and although the earliest 
treatment was in 1988, the median follow up time was 21 
months, therefore longer follow up is required.
We recognise that there are many other treatment options 
in management of PRV and ET. Hydroxycarbamide and 
anagrelide are two of the commonest cytoreductive agents, 
however these drugs are not without side effects and 
limitations. Hydroxycarbamide, an oral anti-metabolite, 
is often first line in the treatment of PRV and ET, usually 
in combination with aspirin. It is however associated with 
nausea, skins rashes, leg ulceration and myelosuppression. 
Anagrelide hydrochloride is second line in those with high 
risk ET. It is a phosphodiesterase inhibitor which also blocks 
megakaryocyte differentiation and proliferation, however 
it may be associated with headache, dizziness, palpitations 
and diarrhoea. Anagrelide has also been associated with an 
increase in reticulin deposition in the bone marrow.  The PT-1 
trial by Harrison et al, which compared hydroxycarbamide 
and aspirin to anagrelide and aspirin in high risk ET patients 
clearly demonstrated higher rates of arterial thrombosis, 
major haemorrhage and transformation to myelofibrosis in 
the anagrelide arm12.
Anagrelide is also associated with arrhythmias and 
cardiomyopathy and therefore may not be suitable for patients 
with cardiovascular disease, which is often more prevalent in 
the elderly.
These cytoreductive drugs require regular monitoring 
accompanied by regular blood counts and dose adjustments. 
Good compliance is required for these drugs to be effective. 
From our review, we are able to conclude that 32P is a well-
tolerated and efficacious treatment option in the elderly. 32P is 
cost effective and has the benefit of reducing the monitoring 
and adjustments needed when on cytoreductive agents. As it 
is given as an injection, compliance is measurable.  It offers 
an alternative option to controlling blood counts when other 
cytoreductive methods are ineffective or limited due to their 
side-effect profile. 
32P will continue to be offered to elderly patients in our 
practice.
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